Results

Total Results: 1,569 records

Showing results for "discussed".

1. What do we know about how evidence of harm and benefit is communicated in other countries? (ppt file)
   effectivehealthcare.ahrq.gov/sites/default/files/communicating_risk_international_king.ppt
   January 01, 2005 - Evidence Implicit Discusses various treatments, but no direct comparison of alternatives Yes, both discussed … Explore with doctor and find best drug for person Narrative, Q&A format, Table of bisphos-phonates Not discussed … GI bleeding Yes, sort out benefit, risk, cost of choices Narrative, Q&A, Price comparisonchart Not discussed

2. Methods White Paper: Improving the Utility of Evidence Synthesis for Decision Makers in the Face of Insufficient Evidence (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/pdf/improving-utility-evidence-synthesis-white-paper.pdf
   April 01, 2021 - We discussed issues until no one voiced disagreements. 4 Findings Literature Review … Decisionmaking with insufficient evidence (n=27): these papers discussed a. challenges of decisionmaking … Sixteen (76%) discussed information from Key Informant (KI) interviews within the findings of their … in peer review feedback Major issues with scoping of review discussed in peer review feedback … in peer review feedback Major issues with scoping of review discussed in peer review feedback

3. PULMONARY with "Discussions" in Exec Summary (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1506.pdf
   October 01, 2015 - PULMONARY with "Discussions" in Exec Summary AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 13: Pulmonary Disease, Including Asthma Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Ro…

4. PULMONARY with "Discussions" in Exec Summary (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1512.pdf
   December 01, 2015 - PULMONARY with "Discussions" in Exec Summary AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 13: Pulmonary Disease, Including Asthma Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers L…

5. PULMONARY with "Discussions" in Exec Summary (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1412.pdf
   October 01, 2015 - PULMONARY with "Discussions" in Exec Summary AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 13: Pulmonary Disease, Including Asthma Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Ro…

6. PULMONARY with "Discussions" in Exec Summary (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/13_pulmonary_potential_high_impact_june_2012.pdf
   January 01, 2012 - PULMONARY with "Discussions" in Exec Summary AHRQ Healthcare Horizon Scanning System – Potential High Impact Interventions Report Priority Area 13: Pulmonary Disease, Including Asthma Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gai…

7. PULMONARY with "Discussions" in Exec Summary (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1312.pdf
   December 01, 2013 - PULMONARY with "Discussions" in Exec Summary AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 13: Pulmonary Disease, Including Asthma Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither…

8. PULMONARY with "Discussions" in Exec Summary (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1306.pdf
   June 01, 2013 - PULMONARY with "Discussions" in Exec Summary AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 13: Pulmonary Disease, Including Asthma Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither…

9. PULMONARY with "Discussions" in Exec Summary (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/pulmonary_hi_impact.pdf
   April 01, 2012 - PULMONARY with "Discussions" in Exec Summary AHRQ Healthcare Horizon Scanning System – Potential High Impact Interventions Report Priority Area 13: Pulmonary Disease including Asthma Potential High Impact Interventions Report Prepared for: Agency for Healthcare Research and Quality U.S. Departme…

10. PULMONARY with "Discussions" in Exec Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1406.pdf
    June 01, 2014 - PULMONARY with "Discussions" in Exec Summary AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 13: Pulmonary Disease, Including Asthma Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither…

11. PULMONARY with "Discussions" in Exec Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/13_pulmonary_potential_high_impact_2012-12-11.pdf
    January 01, 2012 - PULMONARY with "Discussions" in Exec Summary AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 13: Pulmonary Disease, Including Asthma Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither…

12. Comments to Effective Heath Care Program Draft Documents (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/registries-guide-2nd-edition_disposition-comments.pdf
    March 03, 2010 - The white papers have been drafted and reviewed and were discussed at an AHRQ‐sponsored meeting in April … These issues are broad and may best be discussed in a new white paper. … Any recognized potential for bias should be discussed in any publications resulting from the registry … The concept of "representative of the target population" is discussed in detail in both the design and … Any recognized potential for bias should be discussed in any publications resulting from the registry

13. Disposition of Comments Report for CER 226: Labor Dystocia (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/cer-226-labor-dystocia-comments.pdf
    May 14, 2020 - We have added to the introduction a reference to changes over time, which is discussed in more detail … PMID: 29733840), as discussed in this very recent opinion piece. … This is not discussed up front, yet in the results it is clear that unless a study was conducted in … We agree this is an issue, which is discussed in the Discussion section. … Discussion/ Conclusion TEP Reviewer #2 The findings are appropriately discussed, particularly related

14. Disposition of Comments Report for Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/asthma-immunotherapy-2010_disposition-comments.pdf
    January 01, 2010 - As discussed in the methods and in the results sections, we requested the Information Packages from … As discussed in the methods and in the results sections, we requested the Information Packages from … As discussed in the methods and in the results sections, we requested the Information Packages from … We have discussed this in the Applicability section. … SLIT and SCIT are analyzed and discussed in separate chapters and the conclusion discusses the findings

15. Updating the Framework for Agency for Healthcare Research and Quality’s National Healthcare Quality and Disparities Report (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/updating-framework-disposition-comments.pdf
    July 11, 2025 - Reviewers discussed adding a population health perspective to the framework, the role of value in the

16. Comparative Effectiveness Review No. 266_Cervical Degenerative Disease Treatment: A Systematic Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-266-cdd-executive-summary.pdf
    November 01, 2023 - Methods are discussed in more detail in the full report. … Results are discussed in more detail in the full report.

17. Management of Insomnia Disorder (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/insomnia_consumer.pdf
    August 01, 2017 - diphenhydramine (Sominex®) and doxylamine (Unisom®), and the dietary supplement melatonin are not discussed … Food and Drug Administration (FDA) are discussed in more detail on pages 7 and 8. 6 Medicines Possible … According to the FDA, all of the medicines discussed in this summary can cause: � Impaired alertness

18. Treatment for Restless Legs Syndrome Disposition of Comments Report (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/restless-legs_disposition-comments.pdf
    November 27, 2012 - We have more carefully discussed gabapentin enacarbil and have corrected the spelling in Table 1. … Primary outcomes were determined by us, discussed with our TEP and described in our protocol. … We respectfully disagree and have discussed the use of these scale scores in primary care with many … Peer Reviewer #9 Discussion Implications of treatment outcome on comorbidities are not discussed … Peer Reviewer #1 Clarity and Usability Yes, with exceptions discussed above under General Comments

19. Evidence-based Practice Center Systematic Review Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/breast-cancer-medications_disposition-comments.pdf
    March 10, 2010 - A statement, “Trials are described further in the review” has been added where they are first discussed … This point is also discussed in the future research section. … This study is discussed in the text for key question 2. … This is discussed in the results and conclusions sections, and is now included as an area for more research … implication that for older women age was not a discriminant) and most importantly is not further discussed

20. Disposition of Comments for CER 178 Newer Medications for Lower Urinary Tract Symptoms (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/prostatic-hyperplasia-medications_disposition-comments.pdf
    May 26, 2016 - While this issue was discussed during topic refinement process of this project, stakeholders agreed … We discussed the terminology extensively with experts during the Topic Refinement and protocol process … We discussed the terminology extensively with experts during the Topic Refinement and protocol process … If mirabegron was discussed as insufficient evidence, then the other anticholinergics with insufficient … We discussed the terminology extensively with experts during the Topic Refinement and protocol process